Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Feb 8, 2016; 5(1): 75-81
Published online Feb 8, 2016. doi: 10.5409/wjcp.v5.i1.75
Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus
Mehmet Yekta Oncel, Omer Erdeve
Mehmet Yekta Oncel, Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, 06230 Ankara, Turkey
Omer Erdeve, Department of Pediatrics, Division of Neonatology, Ankara University School of Medicine Children’s Hospital, 06100 Ankara, Turkey
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Omer Erdeve, MD, Department of Pediatrics, Division of Neonatology, Ankara University School of Medicine Children’s Hospital, Dögol Caddesi, 06100 Ankara, Turkey. omererdeve@yahoo.com
Telephone: +90-505-4812151 Fax: +90-312-2362101
Received: September 28, 2015
Peer-review started: September 28, 2015
First decision: November 3, 2015
Revised: November 22, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: February 8, 2016
Core Tip

Core tip: Regarding to the management of patent ductus arteriosus (PDA) in preterm infants, neonatologists and cardiologists have not reached a consensus on which PDAs to treat, when to treat, and how to treat. Currently, ibuprofen seems to be the first choice due to its higher safety profile, as it is associated with fewer gastrointestinal and renal side effects when compared to indomethacin. PDA closure rates are better with oral than with intravenous ibuprofen. Recent studies suggest that paracetamol can be a medical alternative in the management of PDA with similar efficacy but lower side events than nonsteroidal anti-inflammatory drugs.